The development of malignant gliomas (astrocytomas) involves the accumulation of multiple genetic changes, including mutations in the p53 and retinoblastoma (Rb) cell cycle regulatory pathways. One Rb pathway alteration seen in high-grade astrocytomas is ampli®ca-tion of cyclin dependent kinase-4 (CDK4). To de®ne the function of CDK4 ampli®cation/overexpression in astrocytoma pathogenesis, we generated three transgenic mouse lines that overexpress human CDK4 (hCDK4) in astrocytes using the human glial ®brillary acidic protein (GFAP) promoter. GFAP-hCDK4 mice do not develop brain tumors, but exhibit a small increase in astrocyte number. Cultured astrocytes from these mice do not demonstrate a cell-autonomous growth advantage in vitro and lack properties of transformed cells. To determine whether cdk4 overexpression provides a cooperative growth advantage in vitro, CDK4-overexpressing C6 glioma cell lines were generated and found to exhibit increased cell growth. In addition, GFAP-hCDK4; p53+/ 7 as well as p53+/7; Rb+/7 mice exhibited increased numbers of astrocytes compared to GFAP-hCDK4, p53+/7, or Rb+/7 mice in vivo. No cooperative eect was observed with GFAP-hCDK4; Rb+/7 mice. These results support the hypothesis that cdk4 overexpression alone is not sucient for astrocytoma formation, but can provide a cooperative growth advantage in concert with genetic alterations in the p53 pathway.
The development of malignant gliomas (astrocytomas) involves the accumulation of multiple genetic changes, including mutations in the p53 and retinoblastoma (Rb) cell cycle regulatory pathways. One Rb pathway alteration seen in high-grade astrocytomas is ampli®ca-tion of cyclin dependent kinase-4 (CDK4). To de®ne the function of CDK4 ampli®cation/overexpression in astrocytoma pathogenesis, we generated three transgenic mouse lines that overexpress human CDK4 (hCDK4) in astrocytes using the human glial ®brillary acidic protein (GFAP) promoter. GFAP-hCDK4 mice do not develop brain tumors, but exhibit a small increase in astrocyte number. Cultured astrocytes from these mice do not demonstrate a cell-autonomous growth advantage in vitro and lack properties of transformed cells. To determine whether cdk4 overexpression provides a cooperative growth advantage in vitro, CDK4-overexpressing C6 glioma cell lines were generated and found to exhibit increased cell growth. In addition, GFAP-hCDK4; p53+/ 7 as well as p53+/7; Rb+/7 mice exhibited increased numbers of astrocytes compared to GFAP-hCDK4, p53+/7, or Rb+/7 mice in vivo. No cooperative eect was observed with GFAP-hCDK4; Rb+/7 mice. TheseIntroduction Astrocytomas are the most common primary cancer aecting the central nervous system and are composed of neoplastic astrocytes or glia. The World Health Organization (WHO) strati®es astrocytomas on the basis of their histological appearance into four grades of malignancy, with grade III (anaplastic astrocytoma) and grade IV (glioblastoma multiforme; GBM) representing the most malignant forms (Kleihues and Cavanee, 2000) . Despite aggressive therapy, the median survival of patients diagnosed with a GBM is only 9 ± 12 months and less than 2% of patients will live 5 years. These malignant tumors are hypothesized to develop as the result of the stepwise accumulation of speci®c genetic changes that promote astrocyte proliferation and malignant transformation. Some of these genetic alterations likely represent initiating events important for astrocytoma development while others are late events, associated with malignant progression.
Initiating or early genetic events involve activation of the RAS signaling pathway or inactivation of the p53 tumor suppressor. Support for this assignment derives from studies on two inherited cancer predisposition syndromes in which aected individuals develop astrocytomas at an increased frequency (neuro®broma-tosis 1; NF1 and Li-Fraumeni syndrome; LFS). Approximately 15 ± 20% of children with neuro®bro-matosis 1 (NF1) develop low-grade astrocytomas (Listernick et al., 1999) resulting from loss of the NF1 tumor suppressor, neuro®bromin, which functions as a negative regulator of RAS . Inactivation of NF1 in these astrocytic tumors results in increased RAS pathway activation and provides a growth advantage for astrocytes in vitro and in vivo (Bajenaru et al., 2001; Gutmann et al., 1999) . Similarly, individuals with LFS develop astrocytomas as a result of an inherited mutation in the p53 tumor suppressor gene (Li and Fraumeni, 1969; Bischo et al., 1990) . Moreover, inactivation of the p53 gene in cultured mouse astrocytes results in astrocyte transformation in vitro (Bogler et al., 1995 (Bogler et al., , 1999 Yahanda et al., 1995) .
Genetic alterations observed in high-grade astrocytomas include loss of the p16 tumor suppressor, overexpression/ampli®cation of the epidermal growth factor receptor (EGF-R) (Ekstrand et al., 1992; Wong et al., 1987) and ampli®cation of chromosome 12q containing the MDM2 and cyclin dependent kinase-4 (CDK4) genes (Reifenberger et al., 1994 (Reifenberger et al., , 1996 . Based on their association with grade III and IV, but not grade II, astrocytomas, these changes are thought to represent genetic alterations important for malignant progression. Whereas MDM2 functions as a regulator of the p53 pathway, CDK4 acts to reduce retinoblastoma pathway function. Recent genetic studies on high-grade astrocytomas suggest that alterations in p53 (p53 or MDM2) and Rb pathway (Rb, p16, or cdk4) function are common, but multiple genetic changes in the same pathway are not frequently observed. These results suggest that the cooperative eect of p53 and Rb pathway inactivation is important for malignant progression and that multiple changes within the same pathway may be functionally redundant with regard with astrocytoma pathogenesis.
Our ability to design targeted therapies for these devastating nervous system tumors is heavily predicated on identifying the genetic events that are critical for astrocytoma development and progression. Studies in our laboratory have focused on developing in vivo mouse models for human astrocytomas by generating transgenic and conditional knockout mice in which speci®c initiating and progression-associated genetic changes are introduced in astrocytes. Previous work has demonstrated that astrocyte-speci®c expression of an activated RAS molecule is sucient for astrocytoma formation (Ding et al., 2001) , whereas mice with astrocyte-speci®c expression of the EGF-R mutant, EGF-RvIII, do not form astrocytomas (Ding et al., 2000) . To determine whether overexpression of CDK4 confers a cooperative growth advantage for astrocytes in vivo and is sucient for astrocytoma formation, we generated mice with targeted expression of a human CDK4 molecule in astrocytes. In this report, we demonstrate that three transgenic mouse lines with astrocyte-speci®c CDK4 overexpression do not develop astrocytomas, but exhibit small increases in brain astrocyte number. We further show that CDK4 overexpression provides an additional growth advantage in vitro as well as in vivo when combined with speci®c genetic alterations.
Results

Generation and identification of astrocyte-specific CDK4 transgenic mice
The pGfa2 plasmid containing 2.2 kb of the human GFAP promoter sequence has been previously employed to direct expression of speci®c genes to astrocytes in transgenic mice (Zhou et al., 1997; Wakabayashi et al., 1999; Brenner et al., 1994) . To generate mice with CDK4 overexpression in astrocytes, the 912 bp human CDK4 sequence was subcloned into pGfa2. The resulting 3.6 kb Gfa2.CDK4 construct, containing the human GFAP promoter (2.2 kb), the human CDK4 transgene (0.9 kb) and the mp-1 intronic sequences (0.5 kb), was produced by removing vector sequences with EcoRI digestion (Figure 1a) . After pronuclear microinjection of Gfa2.CDK4 DNA, 81 mice from the ®rst generation were screened for CDK4 positive transgenic pups by PCR ampli®cation of human CDK4. As the human CDK4 is 88% identical to that of mouse, we chose a 5' primer within the hGFAP promoter and a 3' primer at the end of the human CDK4 transgene to speci®cally amplify the human CDK4 transgene. Four founders were identi®ed by PCR ampli®cation (Figure 1b) . Breeding pairs were then established to generate transgenic mouse lines. Germline transmission was established for founders 2, 8, and 27, but not founder 9, which did not transmit the transgene to its ospring.
Southern blotting was performed to con®rm the integration of hCDK4 into the mouse genome DNA for lines 2, 8, and 27. Genomic DNA from each of the three founder lines was digested with EcoRI overnight. When 912 bp human CDK4 sequence was used as a probe, a unique 3.6 kb band was detected in each of the three CDK4+ transgenic lines (Figure 1c ). No such bands were observed in the wild-type littermates (Figure 1c ), indicating that the 3.6 kb human CDK4 Figure 1 Generation of GFAP-hCDK4 transgenic mice. (a) A 3.6 kb construct, containing the human GFAP promoter (2.2 kb), the human CDK4 fragment (0.9 kb) and the mp-1 intronic sequences (0.5 kb), was used to generate hCDK4 transgenic mice by pronuclear microinjection as described in the Materials and methods section. (b) Four founder lines (lines 2, 8, 9 and 27) were identi®ed by PCR ampli®cation using primer sets that speci®cally recognize the GFAP-hCDK4 transgene (*900 nucleotides). No PCR product was observed with DNA from line 3. (c) Southern blot indicates that the 3.6 kb construct was integrated into the genomic DNA of lines 2, 8 and 27. DNA from one GFAPhCDK4 (`+') and one wild-type (`7') littermate mouse from each of the three transgenic lines as determined by PCR was analysed by Southern blot. Ten mg of genomic DNA were digested with EcoRI and hybridized with a probe containing the hCDK4 sequence by [a- In addition, mRNA expression of the human CDK4 transgene in astrocytes was identi®ed by RT ± PCR from each of the three transgenic mouse lines to demonstrate human CDK4 mRNA expression in astrocytes (data not shown). To prove that CDK4 transgenic mouse astrocytes overexpressed human CDK4 protein, equal amounts of total protein from GFAP-hCDK4 and wild-type littermate astrocytes were analysed by Western blotting with a pan anti-CDK4 antibody. We observed a threefold increase in CDK4 expression in GFAP-CDK4+mouse astrocytes from all three transgenic mouse lines compared to wild-type littermates. The results from one representative line are shown in Figure 2a . Because the pan anti-CDK4 antibody recognizes both mouse and human CDK4, we employed a speci®c anti-human CDK4 antibody to detect transgenic expression of human CDK4 by immunoprecipitation. Agarose-conjugated pan anti-CDK4 antibody was used to precipitate CDK4 from astrocyte protein lysates while an antihuman CDK4 antibody was used to detect the CDK4 protein of human origin in the immunoprecipitates by Western blotting. These results demonstrate that human CDK4 is only expressed in GFAP-hCDK4 astrocytes and not in wild-type littermate cultures ( Figure 2b ). We cannot exclude expression of the hCDK4 transgene in other cell types, such as neurons or oligodendrocytes, due to the insensitivity of the human anti-CDK4 antibodies for immunohistochemistry (data not shown). Previous experience in our laboratory with this human GFAP promoter has demonstrated transgene expression in most astrocytes, and not other cell types, in all regions of the brain without signi®cant regional dierences in expression (ML Bajenaru and DH Gutmann, unpublished observations).
The three GFAP-hCDK4 transgenic mouse lines generated in this study were viable, fertile, and did not exhibit any symptoms of brain tumors even after 15 months of age. Transgene-positive mice were indistinguishable from their wild-type littermates in terms of size and weight. The expected numbers of transgene (+) versus wild-type mice were observed in each litter.
CDK4 overexpression provides a small astrocyte growth advantage in vivo, but not in vitro To investigate whether the overexpression of CDK4 in astrocytes provides a growth advantage in vivo, we determined the number of GFAP-immunoreactive cells (astrocytes) in the hippocampus using previously established approaches employed in our analysis of Nf1+/7 mice Bajenaru et al., 2001) . GFAP-hCDK4 mice exhibit a slight increase in astrocyte number (21 ± 26% increase) compared to the wild-type littermates ( Figure 3 ). This result suggests that overexpression of CDK4 provides a small, but signi®cant growth advantage for astrocytes in vivo.
To determine whether astrocyte-speci®c overexpression of CDK4 results in increased astrocyte growth in vitro, astrocytes from the three CDK4 transgenic mouse lines were dissected and cultured. Equal numbers of astrocytes from both GFAP-hCDK4
Figure 2 hCDK4 expression in astrocytes from GFAP-hCDK4 transgenic mice. (a) CDK4 protein expression in the astrocytes of wild-type and GFAP-hCDK4 transgenic mice was determined by Western blotting using a pan-CDK4 antibody. Astrocytes from GFAP-hCDK4 transgenic mice (hCDK4+) have threefold higher CDK4 protein expression than wild-type astrocytes (wt). The arrows indicate the positions of the 34 kDa CDK4 protein and the 55 kDa tubulin molecule, which serves as a loading control. (b) Immunoprecipitation of human CDK4 from cultured mouse astrocytes demonstrates that GFAP-hCDK4 transgenic mouse astrocytes express the human CDK4 protein. Immunoprecipitation and Western blotting was performed as described in the Materials and methods section. Lane 1 contains protein from normal human fetal astrocytes (NHA), while lanes 2 and 3 contain wild-type and GFAP-hCDK4 cultured mouse astrocytes, respectively. Lane 3 demonstrates the expression of human CDK4, identical to that expressed in NHA cells, when antihuman CDK4 antibody is used transgenic mice and wild-type littermates from each of the three lines were seeded for direct counting on day 5 and 10 of culture. We did not observe a cellautonomous growth advantage in astrocytes from any of the three GFAP-hCDK4 transgenic lines (line 2, 8 and 27) compared to wild-type littermate cultures (Figure 4) , despite a threefold increase in CDK4 expression (Figure 2a) . GFAP-hCDK4 astrocytes did not demonstrate a growth advantage under a variety of conditions, including serum stimulation, epidermal growth factor stimulation, serum-free conditions, and growth in soft agar (data not shown). Collectively, these results suggest that CDK4 overexpression provides a minimal growth advantage in vivo, that is insucient for tumor formation.
CDK4 overexpression provides a growth advantage to C6 cells in vitro
To determine whether CDK4 overexpression provides a cooperative growth advantage for astrocytes in vitro, we studied the eect of hCDK4 overexpression on rat C6 glioma cell growth. Initially, we studied the eect of hCDK4 overexpression in a colony suppression assay. As described in the Materials and methods section, equimolar amounts of pcDNA3 vector and pcDNA3.hCDK4 were transfected into C6 cells and selected for 2 weeks in the presence of geneticin. Western blotting demonstrated that the pcDNA3.hCDK4 transfectants expressed human CDK4 using a human-speci®c antibody (Figure 5a ). We observed a 58% increase in colony number in pcDNA3.hCDK4-transfected cultures compared to those transfected with vector alone (Figure 5b,c) .
To con®rm the growth advantage observed with transient overexpression of hCDK4, we generated several stable C6 glioma cell lines that constitutively overexpress hCDK4. Two of these lines, clone 44 and 52, were chosen for further study. Both C6-hCDK4-44 Figure 4 Growth curves for GFAP-hCDK4 transgenic mouse astrocytes. Cultured mouse astrocytes from wild-type and GFAPhCDK4 transgene positive littermates were established from line 2, line 8 and line 27 as described in the Materials and methods section. Direct cell counting was conducted on day 5 and day 10 of culture. No signi®cant growth advantage was observed in GFAP-hCDK4 mouse astrocytes compared to wild-type littermate astrocyte cultures Equimolar amount of pcDNA3.hCDK4 and pcDNA3 were transfected into C6 cells and the number of G418 resistant colonies determined 2 weeks later as described in the Materials and methods section. The number of C6 colonies transfected with human CDK4 was signi®cantly higher than that observed with vector alone. The number of the colonies greater than 1 mm in diameter was determined for each dish. The mean and standard deviation are determined and shown in (c). The single asterisk denotes a statistically signi®cant increase in colony number of each of the three dishes transfected with pcDNA3.hCDK4 compared to those transfected with the pcDNA3 vector (P50.01) and C6-hCDK4-52 expressed human CDK4 by Western blotting with anti-human CDK4 antibody (Figure 6a, top panel) . We observed a threefold increase in CDK4 expression in the hCDK4-expressing lines (clones 44 and 52) compared to vector-transfected clones using a pan-CDK4 antibody (Figure 6a , bottom panel) similar to that achieved in our transgenic mice. Two vector-transfected clones (C6-v1 and C6-v2) were chosen as controls. Equal numbers of C6 cells from each of the four dierent clones were seeded for direct cell counting on days 3, 6 and 9 of culture. Growth curves indicate that both C6-hCDK4-44 and C6-hCDK4-52 exhibited faster growth (*65% increase in cell number on day 9) than the two vector clones on day 6 and day 9 (Figure 6b ). Similar results were obtained using thymidine incorporation (Figure 6c ) and growth in soft agar (Figure 6d) . Collectively, these results support that notion that CDK4 overexpression 
Genetic cooperation between CDK4 overexpression and heterozygosity for p53 in vivo
The results obtained with the C6 glioma cells suggested that while CDK4 overexpression was insucient by itself to promote astrocytoma formation, it likely cooperates with other`initiating' genetic changes to further increase astrocytoma growth and perhaps promote astrocytoma progression. To determine whether CDK4 overexpression might provide a cooperative growth advantage in vivo for astrocytes, we generated mice expressing the GFAP-hCDK4 transgene in combination with heterozygosity for p53 or Rb. Previous work from our laboratory using this heterozygote system to assess genetic cooperativity has demonstrated a cooperative growth advantage for astrocytes doubly heterozygous for Nf1 and p53 (Bajenaru et al., 2001 ). This cooperative growth advantage is re¯ected by the propensity of these compound heterozygotes to develop astrocytomas (Reilly et al., 2000) . We reasoned, based on human tumors studies, that CDK4 overexpression might provide an additional astrocyte growth advantage in combination with reduced p53 function by virtue of the fact that both the p53 and Rb pathways would be aected. Similarly, if CDK4 and Rb function in the same pathway, we would expect that GFAP-hCDK4; Rb+/7 mice would not exhibit a signi®cant increase in astrocyte number compared with Rb+/7 mice in vivo.
We performed these experiments on two independent GFAP-hCDK4 transgenic lines (lines 2 and 8). While identical results were obtained with both lines, the data for only line 2 are described herein. As demonstrated earlier (Figure 3 ), GFAP-hCDK4 transgenic mice exhibit an average 22% increase in astrocyte number in vivo. Mice heterozygous for a targeted mutation in the genes encoding p53 (p53+/7 mice) or Rb (Rb+/ 7 mice), exhibit a 46 and 38% increase in astrocyte number, respectively, compared to wild-type littermates (Figure 7) . Whereas we observed a cooperative astrocyte growth advantage in GFAP-hCDK4; p53+/ 7 mice (69% increase over wild-type) compared to either GFAP-hCDK4 (22% increase over wild-type) or p53+/7 (45% increase over wild-type), no cooperativity was observed in the GFAP-hCDK4; Rb+/7 mice (40% increase over wild-type) compared to a 38% increase in Rb+/7 mice. In addition, mice doubly heterozygous for mutations in both the p53 and Rb genes demonstrate signi®cant cooperativity (90% increase over wild-type) compared to 38 and 45% increases over wild-type in Rb+/7 and p53+/7 mice, respectively. Collectively, these results suggest that genetic alterations in both the p53 and Rb signaling pathways confer a cooperative growth advantage for astrocytes in vivo, but that multiple alterations within the same pathway (Rb+/7 and cdk4 overexpression) have no additive eect on astrocyte growth.
Discussion
Over the past several years, a number of laboratories generated models of human astrocytomas using transgenic mice, conditional gene disruption in astroglial cells, and viral-mediated transduction in vitro and in vivo. Each of these models examine the eects of single genetic changes alone on glioma pathogenesis as well as the cooperative eects of multiple genetic changes on the formation and progression of these brain tumors. Both genetic changes presumed to bè initiating' events Bajenaru et al., 2001; Yahanda et al., 1995; Bogler et al., 1995 Bogler et al., , 1999 Hegi et al., 2000; Reilly et al., 2000) as well as later`progression-associated' changes (Holland et al., 1998; Ding et al., 2000; Serrano et al., 1996) have been studied.
In the study reported herein, we describe the generation of several lines of transgenic mice that overexpress human CDK4 in astrocytes. None of these GFAP-hCDK4 transgenic mice develop astrocytomas. Similar results were obtained using a viral transduction system (Holland et al., 1998) . Moreover, neither our group nor Holland and colleagues found evidence for a signi®cant growth advantage for astrocytes overexpres- Figure 7 GFAP-hCDK4;p53+/7 mice demonstrate further increases in astrocyte number in vivo. The number of GFAPimmunoreactive astrocytes was determined in representative sections of the hippocampus CA1 region from wild-type (wt), GFAP-hCDK4, p53+/7, Rb+/7 as well as GFAP-hCDK4; p53+/7, GFAP-hCDK4; Rb+/7, and p53+/7; Rb+/7 mice. Data is presented for line 2, although similar results were obtained for line 8. Each graph bar represents the average number of astrocytes in the CA1 region of the hippocampus from six consecutive sections per brain from at least three animals per each genotype or line. The mean and standard deviation are shown for each genotype or line. In these experiments, we observed a 22% increase in astrocyte number in the GFAPhCDK4 mice, which was further increased in the GFAP-hCDK4; p53+/7 mice (69% increase versus 46% increase in p53+/7 mice) compared to the GFAP-hCDK4; Rb+/7 mice (40% increase versus 38% increase in Rb+/7 mice; N.S.=not signi®cant). A further increase in astrocyte number was seen in double heterozygous p53+/7; Rb+/7 mice (90% increase) compared with either p53+/7 (46% increase) or Rb+/7 mice (38% increase) alone. The asterisk represents a statistically signi®cant increase in astrocyte number (P50.01) sing cdk4. This observation suggests that cdk4 ampli®cation by itself may not be sucient to signi®cantly increase astrocyte proliferation or promote astrocyte transformation. Holland and coworkers maintained cdk4-transduced astrocytes for 450 days and noted that they initially grew slowly, but eventually increased their doubling times and developed hyperploidy. We could not con®rm these results as we speci®cally studied primary astrocyte cultures that had been maintained for a maximum of three passages to reduce the possibility of acquiring additional genetic alterations as a consequence of continued passage in vitro.
Our inability to observe an increase in astrocyte proliferation in vitro is unlikely to be related to the level of CDK4 overexpression, since both our GFAPhCDK4 transgenic mouse astrocytes and our C6 hCDK4 stable cell lines had similar levels of CDK4 overexpression. In the primary GFAP-hCDK4 astrocyte cultures, the lack of a cell autonomous growth advantage re¯ects the inability of CDK4 overexpression by itself to signi®cantly accelerate cell proliferation in the absence of additional growth regulatory pathway alterations present in the C6 glioma cells. C6 glioma cells harbor alterations in p53 function, including p53 mutation and a decrease in wild-type p53 expression (Yin et al., 1995; Scotto et al., 1998; Timiryasova et al., 1999) as well as RAS pathway activation (Guha et al., 1997) and therefore exhibit changes associated with human astrocytoma formation. In contrast, there is little evidence for Rb pathway dysfunction in C6 cells. We detected Rb protein expression and low levels of p16 protein expression in C6 cells (data not shown), despite a single report describing p16 absence in C6 glioma cells (Schlegel et al., 1999) . The fact that we consistently observed a small increase in astrocyte number in vivo suggests that dysregulated Rb pathway function, such as that provided by CDK4 overexpression, may result in brain context-dependent or developmentally-controlled increases in astrocyte cell number in the absence of continued cell proliferation. Studies are underway to determine the eect of CDK4 overexpression on astrocyte proliferation as a function of astroglial cell dierentiation.
The combined results from the study of ink4a-de®cient mice as well as mice with targeted overexpression of cdk4 and EGF-R in astrocytes supports the notion that late progression-associated events are not sucient to initiate glial tumorigenesis. However, the combination of speci®c initiating and progressionassociated genetic events may be critical for GBM formation. A large proportion of high-grade astrocytomas exhibit alterations in the p53 pathway, resulting from either p53 mutation, ampli®cation of the p53 inhibitor, mdm2, or p14-ARF deletions, suggesting that inactivation of the p53 pathway is an early initiating event (Ichimura et al., 2000) . In contrast, genetic alterations involving the Rb pathway, including Rb loss, CDKN2 inactivation, or cdk4 ampli®cation, are more frequently observed in the grade IV than the grade II and III tumors (Ichimura et al., 2000; Rollbrocker et al., 1996) . These results support the general notion that alterations in the p53 and Rb pathways might synergize to promote GBM formation. In this regard, we observed genetic cooperativity between p53+/7 and cdk4 overexpression with respect to brain astrocyte numbers in vivo. Others have reported that inactivation of both Rb and p53 in external granule cells is sucient for medulloblastoma formation in vivo, whereas loss of either gene alone had no eect (Marino et al., 2000) . Similarly, T antigen fragment inactivation of retinoblastoma family member function in p537/7 mice accelerates brain tumor formation by preventing p53-mediated apoptosis (Symonds et al., 1994; Bowman et al., 1996) . In human high-grade astrocytomas, there is typically complete inactivation of these pathways, in contrast to our experiments examining the eects of p53 heterozygosity. The increased growth advantage in the heterozygous state suggests that CDK4 overexpression on p537/7 background would likely result in a further increase in astrocyte proliferation. Experiments are ongoing in the laboratory to determine whether astrocytomas will form in p53+/7 or p537/7 mice overexpressing hCDK4.
If inactivation of the p53 and Rb pathways is critical for GBM formation, multiple genetic alterations within the same pathway (e.g., mdm2 and p53 or Rb and cdk4 alterations) might be redundant and unnecessary. Although exceptions have been reported, there appears to be an inverse relationship between p16 loss or cdk4 ampli®cation and Rb inactivation (Ueki et al., 1996; Ichimura et al., 2000) . In our GFAP-hCDK4 transgenic mice, we did not observe an eect of combined cdk4 overexpression and Rb+/7 as we had observed for p53 heterozygosity. These results suggest that genetic cooperativity is maximized with alterations in dierent, but synergizing, growth regulatory pathways.
In summary, the generation of mouse models with de®ned genetic alterations relevant to human astrocytoma pathogenesis provides the unique opportunities to examine which genetic events are critical for tumor formation and progression. Additional experiments are planned to determine the eects of cdk4 ampli®cation on mice with astrocyte-speci®c alterations in genes important for tumor initiation. These studies open the door to a more complete understanding of the interplay of genetic changes involved in glial tumorigenesis and oer the possibility of developing re®ned preclinical models for human brain tumors.
Materials and methods
Antibodies and cell culture
Anti-human CDK4 polyclonal antibody (AHZ0222) was purchased from BioSource International (Camarillo, CA, USA) while the pan anti-CDK4 rabbit polyclonal antibody (C22) was obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
C6 rat glioma cells were passaged in DMEM containing 10% fetal bovine serum and penicillin/streptomycin. Primary astrocyte cultures (497% glial ®brillary acidic protein or GFAP-immunoreactive) were prepared from day 2 postnatal pups as previously described (Hewett et al., 1993; Rose et al., 1993) . Astrocyte purity was assessed using cell type-speci®c antibody (GFAP for astrocytes, MAP2 for neurons, and GalC for oligodendrocytes). Brie¯y, cerebral cortices were dissected and enzymatically digested in 0.09% trypsin for 20 ± 30 min. Astrocytes were then plated at 0.5 hemispheres per T25¯ask in plating medium (10% horse serum, 10% fetal bovine serum, 10 ng/ml EGF, penicillin/streptomycin, 2 mM glutamine, 26.2 mM NaHCO 3 , and 20 mM D-glucose in Eagles Minimal Essential Medium). Subcon¯uent astrocyte cultures were passaged in split and growth medium (10% fetal bovine serum, 2 mM glutamine, and penicillin/streptomycin) for growth assays and Western blots. Cultures were used for at passage 1 and 2 only. Each experiment was performed at least twice with identical results.
Mice
Wild-type C57BL6 mice were used for the propagation of the GFAP-CDK4 transgenic mice. p53+/7 and Rb+/7 mice were obtained from Dr Tyler Jacks (Donehower et al., 1992; Jacks et al., 1992 Jacks et al., , 1994 . All strains were maintained as continuous colonies in the Animal Facility at the Washington University School of Medicine. The double heterozygous mice were generated in our Animal Facility by crossing the GFAP-CDK4+ mice with p53+/7 and Rb+/7 mice. The p53 and Rb genotypes were determined using published primer sets. The CDK4 genotype was determined as described below.
Plasmid construction
The plasmid pGfa2 : Lac-Z containing the 2.2 kb human GFAP sequence, which speci®cally directs the expression of LacZ to astrocytes, was obtained from Dr Albee Messing (University of Wisconsin, Madison, WI, USA). The LacZ gene was removed by BamHI digestion and replaced by a human CDK4 fragment (generously provided by Dr Phillip Hinds, Boston, MA, USA). The Gfa2.cdk4 construct (3.6 kb) was linearized and vector sequences removed prior to puri®cation. Pronuclear microinjection of Gfa2.cdk4 DNA was performed by the Neuroscience Transgenic Mouse Facility at Washington University.
Genotyping PCR genotypingMouse tails were treated with 200 ul of tail extraction buer (50 mM Tris-HCl pH 7.4, 1 mM CaCl 2 , 1% Tween-20) plus 25 ul of 1% Proteinase K at 558C overnight. One microliter of tail DNA was subjected to PCR ampli®cation using the following primers: 5'-CATCGC-CAGTCTAGCCCAC-3' and 5'-CGGATCCTCACTCCG-GATTACCTTCATC-3'. Thirty-nine cycles of ampli®cation was performed using an annealing temperature of 628C and the PCR products were resolved by 1% agarose gel electrophoresis. The PCR products with 0.9 kb ampli®ed fragment were classi®ed as transgenic positive genotype.
Southern blot Mouse tail genomic DNA (10 micrograms) was digested with EcoRI and separated by 1% agarose gel electrophoresis followed by capillary transfer onto Hybond-N nylon membranes (Amersham, Piscataway NJ, USA). The human CDK4 fragment (912 bp) was labeled with a-32 PdATP using the Prime-a-gene Labeling system (Promega, Madison, WI, USA). The puri®ed probe hybridized to the membranes at 428C overnight, washed three times in 26SSC, 0.1% SDS at 608C, and exposed at 7808C for 48 h.
RT ± PCR RNA was extracted from primary cultured astrocytes of dierent genotypes using TRIzol Reagent (Gibco-BRL Life Technologies). Three micrograms of RNA was subjected to ®rst-strand synthesis using random polyhexamer primers and Superscript II reverse transcriptase (Gibco-BRL Life Technologies) at 428C. Five microliters of ®rst-strand cDNA were subjected to PCR using the following primers: 5'-GCATCACCTCCGCTGCTCGC-3' and 5'-CGGATCCTCACTCCGGATTACCTTCATC-3' for 39 cycles with a 628C annealing step.
Western blotting and immunoprecipitation Western immunoblotting was performed as previously described using ECL chemiluminescent detection (Amersham, Arlington Heights, IL, USA). The pan anti-CDK4 was used at a 1 : 1000 dilution at room temperature for 1 h while the anti-human CDK4 antibody was used at a 1 : 100 dilution at 48C overnight. Immunoprecipitation experiments were performed by incubating 1 mg of total protein lysate with a 1 : 50 dilution of CDK4 (C-22)-agarose conjugate rotating overnight in the cold room. The next day, the immunoprecipitates were extensively washed in buer containing 50 mM HEPES 7.4, 150 mM NaCl, 1 mM EDTA, 1 mM DTT, 2.5 mM EGTA, 0.1% Tween-20, 10% glycerol, 0.1 mM PMSF, 0.5 mM ATP, 10 mM b-glycerophosphate, 1 mM sodium¯uoride, and 0.1 mM sodium orthovanadate prior to elution by boiling in 26Laemmli buer. Proteins were separated by 12% SDS ± PAGE and transferred onto Immobilon-P membranes (Millipore, Bedford, MA, USA) for immunoblotting.
Colony formation assay Focus formation assays were performed by transfecting C6 rat glioma cells with equimolar amounts of pcDNA3.cdk4 and pcDNA3 vector using Lipofectamine (Gibco-BRL Life Sciences). Five 100 mm plates for each transfection were grown for 14 ± 21 days in the presence of 750 ug/ml of G418. The number of colonies greater than 1 mm in diameter was counted after Crystal Violet staining and the mean and standard deviation determined for each transfection. Each experiment was performed at least twice with identical results.
Thymidine incorporation and growth in soft agar Thymidine incorporation was performed as previously described (Bajenaru et al., 2001) . Brie¯y, C6 cell clones were incubated in serum-free DMEM for 24 h with 1 mCurie tritiated thymidine added for the last 4 h. Each condition was performed in quadruplicate and cells were harvested in 0.2 M NaOH. Thymidine incorporation was measured on a scintillation counter and the mean and standard deviation were determined for each clone. Each experiment was performed at least twice with identical results. Soft agar growth assays were performed in quadruplicate on transfected C6 clones. Brie¯y, one hundred C6 cells were plated in each 24-well plate well with medium containing 0.3% Noble agar for 14 ± 21 days. The number of colonies was determined by direct counting on an inverted microscope and the mean and standard deviation determined for each clone.
